Roche has announced a $50 billion investment in the United States over the next five years, aiming to create over 12,000 jobs. This strategic move is in response to potential tariffs from the Trump administration targeting Swiss pharmaceutical imports. The investment will expand manufacturing and distribution centers in Kentucky, Indiana, New Jersey, and California.

New facilities include a gene therapy plant in Pennsylvania, a continuous glucose monitoring site in Indiana, a weight loss drug factory at an undisclosed location, and a cardiovascular, renal, and metabolism research center in Massachusetts. CEO Thomas Schinecker emphasized that this initiative will position Roche to export more medicines from the U.S. than it imports, reinforcing the company's commitment to U.S. innovation and growth. This development follows similar U.S. investment plans by Novartis, Eli Lilly, and Johnson & Johnson.